Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
CD20 positive
i
Other names:
CD20, MS4A1, Membrane Spanning 4-Domains A1, Membrane-Spanning 4-Domains, Subfamily A, Member 1, Leukocyte Surface Antigen Leu-16, B-Lymphocyte Antigen CD20, CD20 Antigen, Membrane-Spanning 4-Domains Subfamily A Member 1, B-Lymphocyte Cell-Surface Antigen B1, B-Lymphocyte Surface Antigen B1, CD20 Receptor, LEU-16, CVID5, MS4A2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
494216
Related biomarkers:
Expression
Others
‹
CD20 positive + TMB-L (1)
CD20 positive + TMB-L (1)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
CD20 positive
Chronic Lymphocytic Leukemia
CD20 positive
Chronic Lymphocytic Leukemia
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
CD20 positive
Diffuse Large B Cell Lymphoma
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
Rixathon (rituximab biosimilar)
Sensitive
:
A1
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
Rixathon (rituximab biosimilar)
Sensitive
:
A1
CD20 positive
Non-Hodgkin’s Lymphoma
CD20 positive
Non-Hodgkin’s Lymphoma
rituximab-arrx
Sensitive: A1 - Approval
rituximab-arrx
Sensitive
:
A1
rituximab-arrx
Sensitive: A1 - Approval
rituximab-arrx
Sensitive
:
A1
CD20 positive
Chronic Lymphocytic Leukemia
CD20 positive
Chronic Lymphocytic Leukemia
rituximab-arrx
Sensitive: A1 - Approval
rituximab-arrx
Sensitive
:
A1
rituximab-arrx
Sensitive: A1 - Approval
rituximab-arrx
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
CD20 positive
Diffuse Large B Cell Lymphoma
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
CD20 positive
Diffuse Large B Cell Lymphoma
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
CD20 positive
Follicular Lymphoma
CD20 positive
Follicular Lymphoma
rituximab + ibritumomab tiuxetan
Sensitive: A1 - Approval
rituximab + ibritumomab tiuxetan
Sensitive
:
A1
rituximab + ibritumomab tiuxetan
Sensitive: A1 - Approval
rituximab + ibritumomab tiuxetan
Sensitive
:
A1
CD20 positive
Chronic Lymphocytic Leukemia
CD20 positive
Chronic Lymphocytic Leukemia
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
CD20 positive
Non-Hodgkin’s Lymphoma
CD20 positive
Non-Hodgkin’s Lymphoma
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
CD20 positive
Chronic Lymphocytic Leukemia
CD20 positive
Chronic Lymphocytic Leukemia
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
CD20 positive
Follicular Lymphoma
CD20 positive
Follicular Lymphoma
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
CD20 positive
Non-Hodgkin’s Lymphoma
CD20 positive
Non-Hodgkin’s Lymphoma
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
CD20 positive
Diffuse Large B Cell Lymphoma
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
CD20 positive
Non-Hodgkin’s Lymphoma
CD20 positive
Non-Hodgkin’s Lymphoma
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
CD20 positive
Burkitt Lymphoma
CD20 positive
Burkitt Lymphoma
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
CD20 positive
Childhood B Acute Lymphoblastic Leukemia
CD20 positive
Childhood B Acute Lymphoblastic Leukemia
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
CD20 positive
Chronic Lymphocytic Leukemia
CD20 positive
Chronic Lymphocytic Leukemia
obinutuzumab
Sensitive: A1 - Approval
obinutuzumab
Sensitive
:
A1
obinutuzumab
Sensitive: A1 - Approval
obinutuzumab
Sensitive
:
A1
CD20 positive
Small Lymphocytic Lymphoma
CD20 positive
Small Lymphocytic Lymphoma
obinutuzumab
Sensitive: A1 - Approval
obinutuzumab
Sensitive
:
A1
obinutuzumab
Sensitive: A1 - Approval
obinutuzumab
Sensitive
:
A1
CD20 positive
Acute Lymphocytic Leukemia
CD20 positive
Acute Lymphocytic Leukemia
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
CD20 positive
B Acute Lymphoblastic Leukemia
CD20 positive
B Acute Lymphoblastic Leukemia
rituximab + blinatumomab
Sensitive: A2 - Guideline
rituximab + blinatumomab
Sensitive
:
A2
rituximab + blinatumomab
Sensitive: A2 - Guideline
rituximab + blinatumomab
Sensitive
:
A2
CD20 positive
Non-Hodgkin’s Lymphoma
CD20 positive
Non-Hodgkin’s Lymphoma
rituximab + copanlisib
Sensitive: B - Late Trials
rituximab + copanlisib
Sensitive
:
B
rituximab + copanlisib
Sensitive: B - Late Trials
rituximab + copanlisib
Sensitive
:
B
CD20 positive
Lymphoma
CD20 positive
Lymphoma
rituximab + copanlisib
Sensitive: B - Late Trials
rituximab + copanlisib
Sensitive
:
B
rituximab + copanlisib
Sensitive: B - Late Trials
rituximab + copanlisib
Sensitive
:
B
CD20 positive
Follicular Lymphoma
CD20 positive
Follicular Lymphoma
rituximab-abbs
Sensitive: C1 - Off-label
rituximab-abbs
Sensitive
:
C1
rituximab-abbs
Sensitive: C1 - Off-label
rituximab-abbs
Sensitive
:
C1
CD20 positive
Diffuse Large B Cell Lymphoma
CD20 positive
Diffuse Large B Cell Lymphoma
epcoritamab-bysp
Sensitive: C2 – Inclusion Criteria
epcoritamab-bysp
Sensitive
:
C2
epcoritamab-bysp
Sensitive: C2 – Inclusion Criteria
epcoritamab-bysp
Sensitive
:
C2
CD20 positive
Follicular Lymphoma
CD20 positive
Follicular Lymphoma
epcoritamab-bysp
Sensitive: C2 – Inclusion Criteria
epcoritamab-bysp
Sensitive
:
C2
epcoritamab-bysp
Sensitive: C2 – Inclusion Criteria
epcoritamab-bysp
Sensitive
:
C2
CD20 positive
Lymphoma
CD20 positive
Lymphoma
copanlisib
Sensitive: C2 – Inclusion Criteria
copanlisib
Sensitive
:
C2
copanlisib
Sensitive: C2 – Inclusion Criteria
copanlisib
Sensitive
:
C2
CD20 positive
Follicular Lymphoma
CD20 positive
Follicular Lymphoma
IMM0306
Sensitive: C2 – Inclusion Criteria
IMM0306
Sensitive
:
C2
IMM0306
Sensitive: C2 – Inclusion Criteria
IMM0306
Sensitive
:
C2
CD20 positive
Chronic Lymphocytic Leukemia
CD20 positive
Chronic Lymphocytic Leukemia
Sensitive: C3 – Early Trials
Sensitive
:
C3
Sensitive: C3 – Early Trials
Sensitive
:
C3
CD20 positive
Diffuse Large B Cell Lymphoma
CD20 positive
Diffuse Large B Cell Lymphoma
venetoclax + obinutuzumab
Sensitive: C3 – Early Trials
venetoclax + obinutuzumab
Sensitive
:
C3
venetoclax + obinutuzumab
Sensitive: C3 – Early Trials
venetoclax + obinutuzumab
Sensitive
:
C3
CD20 positive
Non-Hodgkin’s Lymphoma
CD20 positive
Non-Hodgkin’s Lymphoma
rituximab + ALX148
Sensitive: C3 – Early Trials
rituximab + ALX148
Sensitive
:
C3
rituximab + ALX148
Sensitive: C3 – Early Trials
rituximab + ALX148
Sensitive
:
C3
CD20 positive
B Acute Lymphoblastic Leukemia
CD20 positive
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
CD20 positive
Non-Hodgkin’s Lymphoma
CD20 positive
Non-Hodgkin’s Lymphoma
rituximab + PF-05082566
Sensitive: C3 – Early Trials
rituximab + PF-05082566
Sensitive
:
C3
rituximab + PF-05082566
Sensitive: C3 – Early Trials
rituximab + PF-05082566
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login